GlassScriptPhysician profile
Pankaj Baluja
NPI 1063480309
$1,829.62
in general payments reported to CMS, 2019-2025
26 companies · $412 in 2025
The $412 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $328 · 2021: $94.40 · 2022: $333 · 2023: $116 · 2024: $547 · 2025: $412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,030 · Education: $44.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,030.21 |
| Education | $44.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $313.39 | 2019-2025 | Jynarque |
| Travere Therapeutics, INC. | $303.10 | 2023-2025 | Filspari |
| Bayer Healthcare Pharmaceuticals INC. | $173.07 | 2022-2024 | |
| Ani Pharmaceuticals, INC. | $161.80 | 2022-2025 | Purified Cortrophin Gel |
| Amgen INC. | $130.50 | 2019-2025 | Tavneos, Krystexxa |
| Astrazeneca Pharmaceuticals LP | $108.59 | 2019-2025 | Farxiga |
| Vifor Pharma, INC. | $64.12 | 2019-2025 | Veltassa |
| Novartis Pharmaceuticals Corporation | $62.34 | 2023-2024 | |
| Aurinia Pharma U.S., INC. | $55.96 | 2021-2024 | Lupkynis |
| Ardelyx, INC. | $53.40 | 2024-2025 | Ibsrela |
| Lilly USA, LLC | $50.61 | 2024-2025 | Jardiance, Zepbound, Mounjaro |
| Horizon Therapeutics Plc | $38.77 | 2019-2023 | Krystexxa |
| Fresenius USA Marketing, INC. | $36.82 | 2021-2024 | Velphoro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.47 | 2025 | Jardiance |
| Calliditas Therapeutics US INC. | $30.51 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $27.99 | 2025 | Monoferric |
| Nxstage Medical, INC. | $26.81 | 2022 | |
| Medtronic, INC. | $25.72 | 2023 | Micra |
| Akebia Therapeutics INC | $21.31 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $20.33 | 2019 | |
| Novo Nordisk INC | $19.23 | 2025 | Ozempic |
| Alexion Pharmaceuticals, INC. | $19.09 | 2022 | |
| Glaxosmithkline, LLC. | $17.98 | 2022 | |
| Opko Pharmaceuticals, LLC | $17.53 | 2019 | |
| Scpharmaceuticals INC. | $16.18 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pankaj Baluja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.